Potential value of rapid prostate-specific antigen (PSA) decline, in identifying primary resistance (PRes) to abiraterone acetate (AA) and enzalutamide (ENZ), in pre-treated castration resistant prostate cancer (CRPC) patients (pts).
Antonello Veccia
No relevant relationships to disclose
Orazio Caffo
Honoraria - Janssen
Francesca Maines
No relevant relationships to disclose
Alberto Bonetta
No relevant relationships to disclose
Gilbert Spizzo
No relevant relationships to disclose
Enzo Galligioni
No relevant relationships to disclose